EMA Refused: Reasanz (serelaxin) — Novartis Europharm Ltd

View source ↗

Summary

The EMA refused marketing authorization for Reasanz (serelaxin) by Novartis Europharm Ltd for heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Reasanz (serelaxin)

Snippet

Status: Refused. Therapeutic area: Heart Failure. MAH: Novartis Europharm Ltd. Decision date: 05/08/2014